Skip to main content
OpenTrials
Completed

NCT Number: NCT05294406

Intermittent Preventive Treatment With Dihydroartemisinin-piperaquine in Papua, Indonesia

Malaria in pregnancy is a major cause of maternal and neonatal death in Papua, Indonesia. A recent trial in Papua showed that monthly intermittent preventive treatment (IPTp) with the long-acting artemisinin-based combination dihydroartemisinin-piperaquine (DP) among pregnant women in the second and third trimester was safe, tolerable and more efficacious than the current policy of single screening at antenatal care (ANC) booking and treatment of rapid diagnostic test (RDT)-positive cases. The Ministry of Health (MOH) Indonesia now plans to pilot the strategy in the routine health system in Papua, Indonesia. This study will assess the programme effectiveness of IPTp-DP delivery through antenatal care services and women's adherence to the monthly 3-day DP treatment regimen in a 'real life' setting.

The study will be undertaken in ten community health centres in the lowlands and their associated health posts in Timika city. In the first 18 months, MOH will be trained to implement the intervention using quality improvement (QI) approaches to continuously strengthen service delivery, uptake and adherence through plan-do-study-act cycles. The MOH will also be supported to collect safety data for pharmacovigilance. A mixed-methods evaluation will be conducted towards the end of the pilot using exit interviews to assess delivery effectiveness, home visits to assess adherence, and qualitative research to explore provider perceptions of the drivers of successful integration and scalability, and user acceptability. The primary outcome is adherence, defined as the proportion of pregnant women who receive the first dose of IPTp-DP by directly observed therapy (DOT) at ANC, have received the correct number of DP tablets for subsequent doses, and when visited at home have verified they completed the course. The net cost-effectiveness of implementing IPTp-DP and of the current policy of single screening and treatment (SST) in the routine health system will be assessed and compared. Net cost-effectiveness means that cost savings from averted malaria will be deducted from the intervention costs. The incremental financial cost of implementing IPTp-DP from the provider (MOH) perspective at scale in Papua, Indonesia, will also be estimated.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Malaria in Pregnancy

Age range

15 year–49 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Yayasan Pengembangan Kesehatan dan Masyarakat Papua

Timika, Special Region of Papua, 99910, Indonesia

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Health facilities (pilot implementation)

  • Antenatal services must be operational and accessible
  • Midwives/nurses have been trained to prescribe IPTp-DP

Healthcare providers

  • Healthcare providers responsible for providing antenatal care services, and facility managers
  • District and provincial health managers

Pregnant women

  • Pregnant women aged 15-49 years
  • Women in 2nd/3rd trimester of pregnancy
  • HIV negative (where status is known)

Community members

  • community leaders
  • community health care workers
  • husbands of pregnant women

Exclusion criteria

Health facilities (pilot implementation)

  • Health facilities which have accessibility issues and will not be enrolled in the pilot.

Healthcare providers

  • Health workers providing ANC and IPTp-DP services in health facilities who have provided services for <1 month.

Pregnant women

  • Women with communication or language problems including not being able to speak Indonesian.
  • Pregnant women who are unwell during interview
  • Pregnant women who move outside the pilot implementation areas.

Treatment and study plan

Intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin-piperaquine

Drug

Pregnant women attending routine antenatal care visits in their second and third trimester are given monthly IPTp consisting of a treatment dose of dihydroartemisinin-piperaquine (3 tablets per day for 3 days, 9 tablets total)

Primary outcomes

  1. Adherence in pregnant women

    Time frame: At study completion, an average of 10 months

    The proportion of pregnant women who receive the first dose of IPTp-DP by DOT at ANC clinic and have the correct number of DP tablets for subsequent doses on exiting, who when visited at home verify they have completed the treatment (self report and pill counts)

  2. Delivery effectiveness

    Time frame: At study completion, an average of 10 months

    The proportion of women attending ANC clinic treated appropriately according to the IPTp-DP guidelines, defined as the first dose given by directly observed therapy (DOT) on day-1 plus adequate doses to take home for days 2 and 3. Women's understanding of the treatment regimens given during that ANC visit will also be assessed.

Sponsors and collaborators

Lead sponsor

Liverpool School of Tropical Medicine

Other

Collaborators

  • Gadjah Mada University
  • Indonesia-MoH
  • Yayasan Pengembangan Kesehatan dan Masyarakat Papua (Timika Research Facility)

Registry information

Official study title

Evaluation of a Pilot Implementation of Intermittent Preventive Treatment With Dihydroartemisinin-piperaquine to Prevent Adverse Birth Outcomes in Papua, Indonesia

Acronym: STOPMiP-2

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Mar 24, 2022
Registry last updated
Mar 15, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.